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In setting hemoglobin A1c (HbA1c) targets,
physicians must consider individualized
risks and beneﬁts of tight glycemic control
(1,2) by recognizing that the risk-beneﬁt
ratio may become unfavorable in certain
patients, including the elderly and/or
those with multiple comorbidities (3,4).
Customization of treatment goals based
on patient characteristics is poorly under-
stood, partly due to insufﬁcient data on
physicians’ decisions in setting targets.
We used the National Health and Nutri-
tion Examination Survey (NHANES) to an-
alyze patient-reported HbA1c targets set
by physicians and to test whether targets
are correlatedwith patient characteristics.
Data from the NHANES waves 2005–
2006, 2007–2008, 2011–2012, and 2013–
2014 (the 2009–2010 wave lacked HbA1c
data) comprised 2,641 individuals with
self-reported diabetes, of which 1,782
responded to the question, “What does
[your doctor] say [your] ‘A1C’ level should
be?” On the basis of the distribution
of responses, we analyzed the follow-
ing targets: ,6%, ,7%, and higher
cutoffs (,8%, 9%, and 10%) combined.
Using ordered logistic regression, we
assessed the inﬂuence of age; sex; race;
diabetes duration; comorbidities; BMI;
variables on physical, mental, and bio-
logical health; and health care utiliza-
tion. We used NHANES sample weights
to calculate population rates of target
HbA1c categories across the surveywaves.
We speciﬁed and ﬁt an ordered logistic re-
gression with survey year as a ﬁxed effect
to assesswhether the covariates inﬂuenced
target decisions. ANOVA was used to test
the differences across the subsamples.
Of 1,782 respondents, 958 (54%)
reported a target; others responded
that they did not know or that no target
was set. Patients in the two unknown
target categories were comparable
with patients in the known target cate-
gories on the majority of variables. Only
4% of our sample reported target
HbA1c.7%. Twenty-six percent of those
reporting that a target was not set were
over the age 75 years, signiﬁcantly
higher than in other target categories
(P , 0.05). Seventy percent of patients
who were not aware of their target
HbA1c were nonwhite, which was also
signiﬁcantly higher than in other cate-
gories (P, 0.05), except for higher cut-
offs. Weighted proportions of response
categories show that the proportion re-
sponding “do not know” consistently de-
clined from 2005 to 2013: 30% (95% CI
22–39) of patients were not aware of
their target HbA1c in 2005, compared
with 10% (6–14) in 2013. Changes to
other response categories were not
statistically signiﬁcant over time.
Figure 1 summarizes the results of
regression analysis on patients who
reported a target level (n 5 958). Vari-
ables representing demographics (age,
sex, race); medical history (comorbid-
ities, BMI, duration of diabetes); biological,
physical, andmental health (self-reported
health, physical activity, level of disability,
memory loss or confusion, health com-
pared with last year); and health service
use were not correlated with reported
target HbA1c. The odds ratios for inde-
pendent variables of target HbA1c (ex-
cept for the ﬁxed-effect variable) were
within a narrow range close to unity.
Compared with 2005–2006, the odds
of physicians in 2013 setting the target
one unit lower decreased by 41% (OR
0.58 [95% CI 0.39–0.87]). The overall pat-
tern of null effects remained when age
and comorbidity were combined. The
proportion of target HbA1c,7% in young
and healthy patients (,45 years old with
no comorbidities) was 61% (95% CI 49–
71), compared with 62% (95% CI 52–72)
in those older than 65 years with at least
two comorbidities.
Although self-reported HbA1c targets
(and awareness of targets) have in-
creased over the past decade, the tar-
gets remained very low. Additionally,
we did not ﬁnd any evidence that U.S.
physicians systematically consider im-
portant patient-speciﬁc information
when selecting the intensity of glycemic
control. Rising targets seen during the
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study period may reﬂect gradual adop-
tion of the 2010 American Diabetes
Association recommendation to encour-
age more relaxed HbA1c targets for the
elderly (1) and/or changes in quality
measures for diabetes control. One par-
allel explanation is that more contem-
porary quality metrics permit payers
to equally focus on disincentivizing
poor HbA1c control (e.g., HbA1c .9%),
whereas prior metrics were simple bi-
nary targets sensitive only to the pro-
portion of patients achieving tight
control (HbA1c,7%) (5). Such emerging
incentive models could have inﬂuenced
target decisions to shy away from inten-
sive control regardless of the patient-
level characteristics in recent years.
Nevertheless, the lack of variation with
patient characteristics suggests overreli-
ance on a general approach, without
consideration of individual variation in
the risks and beneﬁts (or patient prefer-
ence) of tight control. As “de-adoption”
of tight control in diabetes diffuses into
practice, it must be targeted to those in
whom it is of low value or harmful.
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Figure 1—Target HbA1c decision (outcome) and its association with selected patient-level characteristics with potential impact on the outcome. The
higher the odds ratio, the more intense the target HbA1c.
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